InvestorsHub Logo
icon url

nutriman24

04/23/09 11:06 AM

#20084 RE: Dante64 #20082

Brd. 2 Pharmacology and safety factors affecting
use of flat (rather than
weight-based) dosing of tesetaxel, an
orally administered taxane. (Abstract
#2510)
R. P. Warrell, M. Beeram, E. Spindler, K.
Papadopoulos, A. Patnaik, A. W. Tolcher

Page 281.....http://www.asco.org/ASCO/Downloads/Meetings%20Services/2009%20Annual%20Meeting/Program%20by%20Day.pdf


Page 239

Brd. H3 Survival of advanced melanoma patients
with normal LDH treated with
oblimersen, temozolomide, and nabpaclitaxel.
(Abstract #9080)
A. C. Pavlick, P. Ott, J. Escalon, K.
Madden, E. Yepes, J. Staha, S. Mendoza,
A. Gandhi, H. Yee, L. Liebes